hVIVO plc Award of Share Options (9210B)

TIDMHVO

RNS Number : 9210B

hVIVO plc

16 January 2018

For immediate release 7.00am: 16 January 2018

HVIVO PLC

("hVIVO" or the "Company")

Award of Share Options

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that on 15 January 2018 it awarded the following options over ordinary shares of 5.0p each in the Company to Liam Eves:

 
 Name         Position            Number      Exercise   Date of       Percentage 
                                   of Share    price      Vesting       of issued 
                                   Options     per                      ordinary 
                                   Awarded     Share                    share 
                                                                        capital 
-----------  ------------------  ----------  ---------  ------------  ----------- 
              Executive 
               Vice President,                           20 December 
 Liam Eves     Humatics            136,364      5.0p         2020        0.17% 
-----------  ------------------  ----------  ---------  ------------  ----------- 
 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the persons discharging managerial 
       responsibilities/persons closely associated 
---  ------------------------------------------------------- 
 a)   Name               Liam Eves 
---  -----------------  ------------------------------------ 
 2    Reason for the notification 
---  ------------------------------------------------------- 
 a)   Position/          Executive Vice President, Humatics 
       status             - A person closely associated 
                          with Kym Denny, Chief Executive 
                          Officer of the Company 
---  -----------------  ------------------------------------ 
 b)   Initial            Initial Notification 
       notification/ 
       Amendment 
---  -----------------  ------------------------------------ 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------- 
 a)   Name               hVIVO plc 
---  -----------------  ------------------------------------ 
 b)   Legal Entity       N/A 
       Identifier 
---  -----------------  ------------------------------------ 
 4    Details of the transaction(s): section 
       to be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------- 
 a)   Description        Options over Ordinary Shares of 
       of the             5 pence each 
       financial 
       instrument, 
       type of            ISIN: GB00B6ZM0X53 
       instrument 
       Identification 
       code 
---  -----------------  ------------------------------------ 
 b)   Nature             Award of options over Ordinary 
       of the             Shares in the Company 
       transaction 
---  -----------------  ------------------------------------ 
 c)   Currency           GBP 
---  -----------------  ------------------------------------ 
 d)   Price(s)             Director     Exercise     Volume 
       and volume(s)                          Price (p) 
                          -----------  -----------  -------- 
                           Liam Eves    5.0          136,364 
                          -----------  -----------  -------- 
---  ----------------- 
 
 e)   Aggregated 
       information 
       - Aggregated        136,364 options over Ordinary 
       volume              Shares 
       - Exercise          5.0p 
       price 
---  -----------------  ------------------------------------ 
 f)   Date of            15 January 2018 
       the transaction 
---  -----------------  ------------------------------------ 
 g)   Place of           London Stock Exchange, AIM 
       the transaction 
---  -----------------  ------------------------------------ 
 

For further information please contact:

 
 hVIVO plc                            [phone] 
 Kym Denny (Chief Executive 
  Officer) 
 Graham Yeatman (Chief Financial 
  & Business Officer) 
 
 Media Enquiries                      [phone] 
 Susan Flood (Head of Marketing) 
 
 Numis Securities Limited             [phone] 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black / Michael Burke 
  (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria Foster 
  Mitchell (UK)                       [phone] 
 John Capodanno / Evan Smith 
  (US)                                [phone] 
 

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUVRVRWVAAAAR

(END) Dow Jones Newswires

January 16, 2018 02:00 ET (07:00 GMT)